
Insmed Incorporated
NASDAQ•INSM
CEO: Mr. William H. Lewis J.D., M.B.A.
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Listing Date: 2000-06-01
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Contact Information
Market Cap
$35.77B
P/E (TTM)
-30.0
242.9
Dividend Yield
--
52W High
$212.75
52W Low
$60.40
52W Range
Rank71Top 99.6%
1.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$142.34M+52.36%
4-Quarter Trend
EPS
-$1.75+37.80%
4-Quarter Trend
FCF
-$222.18M+20.35%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Product Revenue Growth Strong Nine-month product revenues reached $342.6M, marking a 32.1% increase driven by ARIKAYCE global sales.
BRINSUPRI US Launch Impact US commercial sales of BRINSUPRI contributed $28.1M to nine-month revenue following August 2025 FDA approval.
Total Assets Increased Total assets grew to $2.36B as of September 30, 2025, up from $2.03B at December 31, 2024.
Risk Factors
Net Loss Significantly Widened Nine-month net loss increased substantially to $948.3M compared to $678.2M in the prior comparable period.
SG&A Expenses Surged SG&A expenses rose 53.4% ($170.1M) YTD, driven by commercial readiness and activities for BRINSUPRI.
Cash Position Decreased Cash and cash equivalents decreased to $334.8M from $555.0M at year-end 2024, reflecting operating cash usage.
Outlook
ARIKAYCE Full Approval Path Anticipate reporting topline data from the ENCORE trial in the first half of 2026 to support full US approval.
Pipeline Advancement Continues Planning Phase 3 initiation for TPIP in Q4 2025; advancing INS1201 and INS1202 gene therapy trials.
Future Capital Requirements Expect future cash requirements to be substantial; company may raise additional capital within the next 12 months.
Peer Comparison
Revenue (TTM)
CAH$234.31B
HUM$126.36B
IQV$15.90B
Gross Margin (Latest Quarter)
HUM100.0%
86.1%
RMD61.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CAH | $48.12B | 30.2 | -55.0% | 16.4% |
| A | $41.96B | 32.1 | 20.6% | 26.4% |
| IQV | $41.02B | 32.0 | 21.4% | 52.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.9%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 19, 2026
EPS:-$1.33
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $142.34M+52.4%|EPS: $-1.75+37.8%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 7, 2025|Revenue: $107.42M+18.9%|EPS: $-1.70-12.4%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 8, 2025|Revenue: $92.82M+22.9%|EPS: $-1.42+34.0%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 20, 2025|Revenue: $363.71M+19.2%|EPS: $-5.57-4.3%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $93.43M+18.2%|EPS: $-1.27+14.4%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 8, 2024|Revenue: $90.34M+17.0%|EPS: $-1.94+9.0%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 9, 2024|Revenue: $75.50M+15.8%|EPS: $-1.06-9.4%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 22, 2024|Revenue: $305.21M+24.4%|EPS: $-5.34-36.6%Miss